Charles Sawyers, M.D.
Charles L. Sawyers is the chair of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center. He is also a professor in the Cell and Developmental Biology Program at Weill Cornell Graduate School of Medical Sciences.
Sawyers studies mechanisms of cancer drug resistance with an eye toward developing novel therapies. He co-discovered the antiandrogen drug enzalutamide, which was approved by the FDA in 2012 for treatment of advanced prostate cancer. He shared the 2009 Lasker-DeBakey Clinical Medical Research Award for the development of the ABL kinase inhibitor imatinib for patients with chronic myeloid leukemia and the second generation ABL inhibitor dasatinib to overcome resistance to imatinib. He received the 2013 Breakthrough Prize in Life Sciences, the 2013 Taubman Prize for Excellence in Translational Medical Science, and the 2015 BBVA Knowledge Award in Biomedicine.
Sawyers is a member of the National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences. He is past president of the American Association for Cancer Research, was appointed to the National Cancer Advisory Board by President Obama, and serves on the board of directors of Novartis.
He received a B.A. from Princeton University and an M.D. from Johns Hopkins University School of Medicine.